Ideas
Moderna's COVID success warrants watching.
Park says Moderna was analyzed during the weekend program because its chart looked unusual, and it made large profits during COVID. He argues a company that performed well in the previous cycle has a higher chance of performing well again, so he placed it in the firm's model portfolio as an interesting watch item, though he does not put low-visibility clinical-stage names into client accounts.
Avoid low-visibility Korean new drug developers.
Park says he generally avoids Korean biotech new drug development stocks for client accounts because their earnings visibility is too low and clinical outcomes are uncertain. This is a deliberate allocation stance rather than a one-stock criticism.
Buy KOSPI below its long-term trend.
Park says high interest rates are currently discounting stocks and creating a chance to buy value/quality shares cheaply. While high rates may persist for a while, he expects they will not keep climbing, and risk indicators such as VIX and high-yield spreads are not yet flashing danger, so the rate-driven correction is a seasonal event around midterm elections rather than a reason to turn bearish on KOSPI.
Record buyback signal; shareholder returns rising.
SK Hynix announced a 40 trillion won buyback and full cancellation equivalent to about 3.3% of issued shares, the largest in Korean listed-company history. It also raised shareholder return from 'within 50%' to 'over 50%' of free cash flow, and with full-year FCF estimated near 180 trillion won the total return could reach 90-100 trillion won, signaling strong confidence and potentially changing stock market flow.
K-defense is top-tier global exporter.
Park highlights that Korea's global arms export ranking jumped from 12th to 4th and its market share rose from 2% to 6%, driven by KAI T50, Hanwha Cheongung2, Hyundai Rotem K2 and other systems. He interprets this as evidence Korean defense is already global top-tier and gaining further momentum.
K2 Poland follow-on shows defense demand.
Hyundai Rotem's K2 tank exports to Poland demonstrated Korea's delivery speed and led to a repeat order: the follow-on 180-unit, roughly 9 trillion won second implementation contract negotiation was completed this month, showing trust and expanding Korean defense presence in Europe.
K9 US contract breaks America open.
Hanwha Aerospace's US subsidiary Hanwha Defense USA won a US Army contract for K9 wheeled self-propelled howitzers, marking the first time a Korean defense company will supply a complete weapons system to the US. The contract has options up to 18 units and validates K9 reliability, rapid development speed, and long-term owner-family investment, opening a path into the US and NATO markets.
First submarine export expands HD Hyundai.
HD Hyundai Heavy Industries is on the verge of its first submarine export after founding. It will complete basic design for Peru's next-generation 1,500-ton submarine by November, then move to contract and construction next year, extending cooperation from surface ships to submarines and securing a Latin America naval bridgehead.
Long-term Treasury yields should fall.
Park argues long-term US Treasury yields must eventually fall because high rates are already causing small-business closures in Korea and weakening US employment. As the economy slows, rates inevitably come down, so the recent spike in the 30-year yield is unlikely to continue at elevated levels.
This Chesley Investment Advisory (체슬리투자자문) video, published August 20, 2026,
features Park Se-ik
discussing MRNA, Korean biotech new drug developers, EWY, 000660.KS, K-defense sector, Hyundai Rotem, 012450.KS, 329180.KS, TLT.
9 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
Park Se-ik
· Tickers:
MRNA,
Korean biotech new drug developers,
EWY,
000660.KS,
K-defense sector,
Hyundai Rotem,
012450.KS,
329180.KS,
TLT